Faculty profile

Kevin Yau

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Kevin Yau

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
42 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Diabetes Mellitus Dialysis End-Stage Kidney Disease Glp-1 Receptor Agonists Pilot Rct

Latest papers

Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.
Kidney international reports · 2026
Provider perspectives of clinical decision support for chronic kidney disease management: a cross-sectional study.
BMC medical informatics and decision making · 2026
How should we measure and interpret glomerular inflammation and what is the best anti-inflammatory approach in IgA nephropathy?
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026 · first author

All 46 publications

Latest funding

Strategies for the management of Atrial Fibrillation in patiEnts receiving Dialysis 2 (SAFE-D2)
CIHR · 2025 · Co-investigator
$1,874,251
STRIDES Kidney: Semaglutide Therapy, Renal health, Individualized diet, Daily exercise, Engagement through coaching and Support Kidney
CIHR · 2025 · Co-investigator
$100,000
Pragmatic randomized trial of High Or Standard PHosphAte Targets in End-stage kidney disease (PHOSPHATE)
CIHR · 2024 · Co-investigator
$1,526,176

All 6 grants and awards

46 publications.

Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.

Tuttle KR, Cherney DZ, Pecoits-Filho R, Pirro M, Yau K, Sahay M

Kidney international reports2026

DOI: 10.1016/j.ekir.2026.106712 PMID: 42656828

Provider perspectives of clinical decision support for chronic kidney disease management: a cross-sectional study.

Goldberg R, Li H, Goldstein CE, Yau K, Ruzycki SM, Donald M, Elliott MJ, Hemmelgarn BR, James MT, Ravani P, Pannu N, Chew D, Acharya D, Harrison TG

BMC medical informatics and decision making2026

DOI: 10.1186/s12911-026-03721-9 PMID: 42482200

How should we measure and interpret glomerular inflammation and what is the best anti-inflammatory approach in IgA nephropathy?

Yau K, Reich HN

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026First author

DOI: 10.1093/ndt/gfaf135 PMID: 40795024

The Oxford Classification Should Remain the Gold Standard for Classification of IgA Nephropathy: PRO.

Yau K, John R, Reich HN

Kidney3602026First author

DOI: 10.34067/kid.0000001082 PMID: 41661685

Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD.

Yau K, Ray JG, Jeyakumar N, Luo B, Abdullah S, Dixon SN, Wing S, Clemens KK, Castrillon-Ramirez F, Udell JA, Meraz-Munoz A, Young A, Harel Z, Perl J, Leiter LA, Garg AX, Cherney DZI, Wald R

American journal of kidney diseases : the official journal of the National Kidney Foundation2026First author

DOI: 10.1053/j.ajkd.2025.09.010 PMID: 41238166

Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).

Clemens KK, Irwin J, Chiu M, Dixon S, Bendo NJ, Varughese P, Vinson AJ, Lapier H, Attalla D, Ernst J, Khan T, Young A, Yau K, Craig L, Reichert S, Sener A, Moist LM

BMJ open2026

DOI: 10.1136/bmjopen-2026-120427 PMID: 42580835

Evaluation of four chatbots in autoimmune liver disease: A comparative analysis.

Daza J, Bezerra LS, Santamaría L, Rueda-Esteban R, Bantel H, Girala M, Ebert M, Van Bömmel F, Geier A, Aldana AG, Yau K, Alvares-da-Silva M, Peck-Radosavljevic M, Ridruejo E, Weinmann A, Teufel A

Annals of hepatology2025

DOI: 10.1016/j.aohep.2024.101537 PMID: 39147133

Long-Term Outcomes of COVID-19 in Patients Receiving Maintenance Dialysis: A Propensity Score Matched Population-Based Cohort Study.

Yau K, Bota SE, McArthur E, Naylor KL, Naik H, Wing S, Blake PG, Hladunewich MA, Levin A, Oliver MJ

Kidney3602025First author

DOI: 10.34067/kid.0000000866 PMID: 40622766

Biomarkers for cardiovascular-kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment.

Yau K, Cherney DZI, Odutayo A

Diabetes, obesity & metabolism2025First author

DOI: 10.1111/dom.70044 PMID: 40859453

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease.

Yau K, Ray JG, Jeyakumar N, Luo B, Abdullah S, McArthur E, Dixon SN, Wing S, Clemens KK, Castrillon-Ramirez F, Udell JA, Meraz-Munoz A, Young A, Harel Z, Perl J, Sridhar VS, Ni H, Yi TW, Leiter LA, Garg AX, Cherney DZI, Wald R

Diabetes care2025First author

DOI: 10.2337/dc24-2811 PMID: 40569823

Something wrong or missing on this profile? Suggest a correction

Kevin Yau

Research

Latest papers

Latest funding

Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.

Provider perspectives of clinical decision support for chronic kidney disease management: a cross-sectional study.

How should we measure and interpret glomerular inflammation and what is the best anti-inflammatory approach in IgA nephropathy?

The Oxford Classification Should Remain the Gold Standard for Classification of IgA Nephropathy: PRO.

Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD.

Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).

Evaluation of four chatbots in autoimmune liver disease: A comparative analysis.

Long-Term Outcomes of COVID-19 in Patients Receiving Maintenance Dialysis: A Propensity Score Matched Population-Based Cohort Study.

Biomarkers for cardiovascular-kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment.

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease.

Strategies for the management of Atrial Fibrillation in patiEnts receiving Dialysis 2 (SAFE-D2)

STRIDES Kidney: Semaglutide Therapy, Renal health, Individualized diet, Daily exercise, Engagement through coaching and Support Kidney

Pragmatic randomized trial of High Or Standard PHosphAte Targets in End-stage kidney disease (PHOSPHATE)

Dial-Bicarb Trial: Lower vs. Higher Dialysate Bicarbonate Concentration in Patients Receiving Hemodialysis

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis (GUARD-1)

Filling Knowledge Gaps for the Success of Ontario Renal Plan 3

Frequent collaborators

Adeera Levin

Anne-Claude Gingras

Jeffrey Perl

Ron Wald

Ayodele Odutayo

Ziv Harel

Amit Garg

Shelly Bolotin

Amber Molnar

Matthew Weir

Mary Beaucage

Maoliosa Donald

Robert Kozak

Kyla Naylor

Pavel Roshanov

Jennifer Irwin

Louise Moist

Henry Li

Susan McKenzie

Martin Pelchat

Ramzi Fattouh

Jeff Kwong

Rami Al Batran

Daniel Figeys

Gihad Nesrallah

Samira Mubareka

Pietro Ravani

Scott Brimble

Satya Dash

Peter Blake

Sonja Reichert